Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data35
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs23
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials23
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing16
The Current Landscape of HTA Framework and Key Challenges14
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies13
Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility12
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”11
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction11
A Basket Trial Design Based on Power Priors10
Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types10
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints10
Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective10
Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions10
0.65802788734436